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1. INTRODUCTION {#myc13096-sec-0005}
===============

Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat.[^1^](#myc13096-bib-0001){ref-type="ref"} Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease.[^2^](#myc13096-bib-0002){ref-type="ref"}, [^3^](#myc13096-bib-0003){ref-type="ref"}, [^4^](#myc13096-bib-0004){ref-type="ref"} Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence.[^5^](#myc13096-bib-0005){ref-type="ref"} In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre.

2. PATIENTS AND METHODS {#myc13096-sec-0006}
=======================

We performed a retrospective chart review of patients with COVID‐19 and ARDS admitted to the medical and surgical ICU at the University Hospital of Cologne, a 1540‐bed teaching hospital between 7 March 2020 and 22 April 2020 (Table [1](#myc13096-tbl-0001){ref-type="table"}).

###### 

Patient characteristics of patients with COVID‐19 associated invasive pulmonary aspergillosis

+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Characteristics                                                                                                   | Patient \#1                                                                                                                                                                                                            | Patient \#2                                                                                                                                                         | Patient \#3                                                                                                                                                                                                    | Patient \#4                                                                                                                                                                                  | Patient \#5                                                                                                                                                                                                                                                  |
+===================================================================================================================+========================================================================================================================================================================================================================+=====================================================================================================================================================================+================================================================================================================================================================================================================+==============================================================================================================================================================================================+==============================================================================================================================================================================================================================================================+
| Gender                                                                                                            | Female                                                                                                                                                                                                                 | Male                                                                                                                                                                | Male                                                                                                                                                                                                           | Male                                                                                                                                                                                         | Female                                                                                                                                                                                                                                                       |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Age (y)                                                                                                           | 62                                                                                                                                                                                                                     | 70                                                                                                                                                                  | 54                                                                                                                                                                                                             | 73                                                                                                                                                                                           | 54                                                                                                                                                                                                                                                           |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Medical history                                                                                                   | Lap. cholecystectomy for cholecystitis                                                                                                                                                                                 | Vertebral disc prolapse left L4/5, flavectomy and nucleotomy                                                                                                        | Arterial hypertension                                                                                                                                                                                          | Arterial hypertension                                                                                                                                                                        | No                                                                                                                                                                                                                                                           |
|                                                                                                                   |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
|                                                                                                                   | Arterial hypertension                                                                                                                                                                                                  | Ex‐smoker (4 months previously)                                                                                                                                     | Diabetes mellitus                                                                                                                                                                                              | Bullous Emphysema                                                                                                                                                                            |                                                                                                                                                                                                                                                              |
|                                                                                                                   |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
|                                                                                                                   | Obesity with sleep apnea (BMI 31.5)                                                                                                                                                                                    |                                                                                                                                                                     | Aneurysm coiling right A. vertebralis                                                                                                                                                                          | Smoker                                                                                                                                                                                       |                                                                                                                                                                                                                                                              |
|                                                                                                                   |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
|                                                                                                                   | Hypercholesterolemia                                                                                                                                                                                                   |                                                                                                                                                                     |                                                                                                                                                                                                                | Severe COPD (GOLD 3)                                                                                                                                                                         |                                                                                                                                                                                                                                                              |
|                                                                                                                   |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
|                                                                                                                   | Ex‐smoker (30 PY; 5 y previously)                                                                                                                                                                                      |                                                                                                                                                                     |                                                                                                                                                                                                                | Previous Hepatitis B                                                                                                                                                                         |                                                                                                                                                                                                                                                              |
|                                                                                                                   |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
|                                                                                                                   | Moderate COPD (GOLD 2)                                                                                                                                                                                                 |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Underlying immuno‐compromising condition                                                                          | (inhalational steroids for COPD)                                                                                                                                                                                       | No                                                                                                                                                                  | (intravenous corticosteroid therapy 0.4 mg/kg/d, total of 13 d)                                                                                                                                                | (inhalational steroids for COPD)                                                                                                                                                             | No                                                                                                                                                                                                                                                           |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| ICU Ward                                                                                                          | MICU                                                                                                                                                                                                                   | MICU                                                                                                                                                                | SICU                                                                                                                                                                                                           | SICU                                                                                                                                                                                         | MICU                                                                                                                                                                                                                                                         |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| ARDS                                                                                                              |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Horowitz‐Index, admission[^12^](#myc13096-bib-0012){ref-type="ref"}                                               | Severe (53 mm Hg)                                                                                                                                                                                                      | Severe (93 mm Hg)                                                                                                                                                   | Moderate (128 mm Hg)                                                                                                                                                                                           | Severe (83 mm Hg)                                                                                                                                                                            | Moderate (167 mm Hg)                                                                                                                                                                                                                                         |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Prone positioning                                                                                                 | Yes                                                                                                                                                                                                                    | Yes                                                                                                                                                                 | Yes                                                                                                                                                                                                            | Yes                                                                                                                                                                                          | Yes                                                                                                                                                                                                                                                          |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| vvECMO                                                                                                            | Yes                                                                                                                                                                                                                    | No                                                                                                                                                                  | No                                                                                                                                                                                                             | No                                                                                                                                                                                           | No                                                                                                                                                                                                                                                           |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Acute renal failure                                                                                               | Yes                                                                                                                                                                                                                    | Yes                                                                                                                                                                 | Yes                                                                                                                                                                                                            | Yes                                                                                                                                                                                          | Yes                                                                                                                                                                                                                                                          |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Dialysis                                                                                                          | No                                                                                                                                                                                                                     | SLEDD                                                                                                                                                               | SLEDD                                                                                                                                                                                                          | SLEDD                                                                                                                                                                                        | No                                                                                                                                                                                                                                                           |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Microbiology                                                                                                      |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Serum GM (\>0.5)                                                                                                  | Negative                                                                                                                                                                                                               | Positive (0.7)                                                                                                                                                      | Negative                                                                                                                                                                                                       | Negative                                                                                                                                                                                     | 2× positive (2.7 and 1.3)                                                                                                                                                                                                                                    |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Fungal culture                                                                                                    | BALF: *Aspergillus fumigatus*                                                                                                                                                                                          | BALF: negative                                                                                                                                                      | TA: *Aspergillus fumigatus*                                                                                                                                                                                    | TA: *Aspergillus* fumigatus                                                                                                                                                                  | TA: negative                                                                                                                                                                                                                                                 |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Susceptibility testing                                                                                            | Azole susceptible[^a^](#myc13096-note-0005){ref-type="fn"}                                                                                                                                                             | Not applicable                                                                                                                                                      | Azole susceptible                                                                                                                                                                                              | Azole susceptible                                                                                                                                                                            | Not applicable                                                                                                                                                                                                                                               |
|                                                                                                                   |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
|                                                                                                                   |                                                                                                                                                                                                                        |                                                                                                                                                                     | Itraconazole MIC 0.380 (mg/L)                                                                                                                                                                                  | Itraconazole MIC 0.380 (mg/L)                                                                                                                                                                |                                                                                                                                                                                                                                                              |
|                                                                                                                   |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
|                                                                                                                   |                                                                                                                                                                                                                        |                                                                                                                                                                     | Voriconazole MIC 0.094 (mg/L)                                                                                                                                                                                  | Voriconazole MIC 0.094 (mg/L)                                                                                                                                                                |                                                                                                                                                                                                                                                              |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Fungal PCR                                                                                                        | BALF: *Aspergillus fumigatus*                                                                                                                                                                                          | BALF: *Aspergillus fumigatus*                                                                                                                                       | BALF: *Aspergillus fumigatus*                                                                                                                                                                                  | TA: *Aspergillus fumigatus*                                                                                                                                                                  | TA: negative                                                                                                                                                                                                                                                 |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| TA/BALF GM (\>0.5)                                                                                                | BALF: Positive (\>2.5)                                                                                                                                                                                                 | BALF: Positive (\>2.5)                                                                                                                                              | BALF: Positive (\>2.5)                                                                                                                                                                                         | Not available                                                                                                                                                                                | Not available                                                                                                                                                                                                                                                |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Definition of IPA                                                                                                 |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| EORTC/MSG Criteria[^8^](#myc13096-bib-0008){ref-type="ref"}                                                       | Not classifiable (no host criterion)                                                                                                                                                                                   | Not classifiable (no host criterion)                                                                                                                                | Not classifiable (no host criterion)                                                                                                                                                                           | Not classifiable (no host criterion)                                                                                                                                                         | Not classifiable (no host criterion)                                                                                                                                                                                                                         |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| (modified) *AspICU* algorithm[^3^](#myc13096-bib-0003){ref-type="ref"}, [^7^](#myc13096-bib-0007){ref-type="ref"} | Putative                                                                                                                                                                                                               | Modified putative[^3^](#myc13096-bib-0003){ref-type="ref"} (GM positivity)                                                                                          | Putative                                                                                                                                                                                                       | Putative                                                                                                                                                                                     | Modified putative[^3^](#myc13096-bib-0003){ref-type="ref"} (GM positivity)                                                                                                                                                                                   |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Virology                                                                                                          |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| PCR                                                                                                               | TA: positive for hMPV and SARS‐CoV‐2 (E‐gene: *C* ~t~ 13.29; S‐gene: *C* ~t~ 12.61)                                                                                                                                    | TA: positive for hMPV and SARS‐CoV‐2(E‐gene: *C* ~t~ 34.29; ORF1 a/b: *C* ~t~ 31.47)                                                                                | TA positive for SARS‐CoV‐2 (E‐gene: *C* ~t~ 29.74; ORF1 a/b: *C* ~t~ 27.86)                                                                                                                                    | TA positive for SARS‐CoV‐2 (E‐gene: *C* ~t~ 21.47; ORF1 a/b: *C* ~t~ 20.12)                                                                                                                  | TA positive for SARS‐CoV‐2 (*C* ~t~ values not available)                                                                                                                                                                                                    |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| CT imaging studies                                                                                                | Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations (Video [S1](#myc13096-sup-0001){ref-type="supplementary-material"}, Figure [1A](#myc13096-fig-0001){ref-type="fig"}) | Ground‐glass opacities with occasional nodules (Video [S2](#myc13096-sup-0002){ref-type="supplementary-material"}, Figure [1B](#myc13096-fig-0001){ref-type="fig"}) | Bilateral ground‐glass opacities, nodular infiltrates with cavities and air crescent sign (Video [S3](#myc13096-sup-0003){ref-type="supplementary-material"}, Figure [1C](#myc13096-fig-0001){ref-type="fig"}) | Ground‐glass opacities with occasional nodules, known bullous emphysema (Video [S4](#myc13096-sup-0004){ref-type="supplementary-material"}, Figure [1D](#myc13096-fig-0001){ref-type="fig"}) | Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video [S5](#myc13096-sup-0005){ref-type="supplementary-material"}, Figure [1E](#myc13096-fig-0001){ref-type="fig"}) |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Therapy                                                                                                           |                                                                                                                                                                                                                        |                                                                                                                                                                     |                                                                                                                                                                                                                |                                                                                                                                                                                              |                                                                                                                                                                                                                                                              |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Antifungal treatment                                                                                              | Voriconazole iv (6/4 mg/kg BW twice daily)                                                                                                                                                                             | Isavuconazole iv (200 mg thrice daily for 2 d; 200 mg once daily from 3 d)                                                                                          | Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily)                                                                                                                       | Voriconazole iv (6/4 mg/kg BW twice daily)                                                                                                                                                   | Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily)                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Antiviral therapy                                                                                                 | Supportive only                                                                                                                                                                                                        | Supportive only                                                                                                                                                     | Hydroxychloroquine, darunavir and cobicistat at external hospital, in house changed to supportive only                                                                                                         | Supportive only                                                                                                                                                                              | Ribavirin, lopinavir/ritonavir at external hospital, in house changed to supportive only                                                                                                                                                                     |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Outcome                                                                                                           | Died                                                                                                                                                                                                                   | Died                                                                                                                                                                | Alive                                                                                                                                                                                                          | Died                                                                                                                                                                                         | Alive                                                                                                                                                                                                                                                        |
+-------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

Abbreviations: ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage fluid; BW, body weight; COPD, chronic obstructive pulmonary disease; *C* ~t~, threshold cycle; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; GOLD, global initiative for chronic obstructive lung disease; hMPV, human metapneumovirus; IPA, invasive pulmonary aspergillosis; kg, kilogram; lap, laparoscopic; LVB, lumbar vertebral body; mg, milligram; MIC, minimal inhibitory concentration; MICU, medical ICU; ORF, open reading frame; PCR, polymerase chain reaction; PY, pack‐year history; SICU, surgical ICU; SLEDD, slow low‐efficient daily dialysis; TA, tracheal aspirate; vvECMO, veno‐venous extracorporeal membrane oxygenation.
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For patient \#1 SARS‐CoV‐2 RT‐PCR Kit (altona Diagnostics) and for patients \#2, \#3 and \#4 cobas® SARS‐CoV‐2 Test (Roche) were used. For patient \#5, kit manufacturer remains unknown. Respective *C* ~t~ values are given in Table [1](#myc13096-tbl-0001){ref-type="table"} where available. hMPV‐PCR was performed with NxTAG® Respiratory Pathogen Panel (Luminex). *Aspergillus* 28S rDNA‐Realtime PCR was performed as in‐house PCR test for screening purposes. Species identification was performed by artus® *Aspergillus* diff. RG PCR kit (Qiagen). For galactomannan testing from serum, bronchoalveolar lavage fluid (BALF) or tracheal aspirate (TA) Platelia *Aspergillus* antigen ELISA (Bio‐Rad Laboratories) was used. Antifungal susceptibility testing was performed using concentration gradient strips on RPMI agar plates. In brief, spore suspensions of the fungal isolates were adjusted to 10^6^ CFU/mL and inoculated with MIC test strips for itraconazole and voriconazole (bioMérieux). MICs were determined visually after 48 hours of incubation at 35°C. VIPcheck™ (Mediaproducts BV) was performed in patient \#1 for early detection of azole resistance.[^6^](#myc13096-bib-0006){ref-type="ref"}

COVID‐19 associated IPA was classified according to the (modified)[^3^](#myc13096-bib-0003){ref-type="ref"} *AspICU* algorithm[^7^](#myc13096-bib-0007){ref-type="ref"} with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion.[^8^](#myc13096-bib-0008){ref-type="ref"} Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table [1](#myc13096-tbl-0001){ref-type="table"}). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki[^9^](#myc13096-bib-0009){ref-type="ref"} and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157).

3. RESULTS {#myc13096-sec-0007}
==========

A 62‐year‐old woman was admitted to our ICU. She was intubated and developed severe ARDS with a Horowitz‐Index of 53 mm Hg. At the contrast‐enhanced CT a combination of emphysema, bilateral ground‐glass opacities with crazy paving and some peripheral nodular consolidations were seen (Video [S1](#myc13096-sup-0001){ref-type="supplementary-material"}, patient \#1, Figure [1A](#myc13096-fig-0001){ref-type="fig"}). Despite prone positioning, the patient required rescue veno‐venous extracorporeal membrane oxygenation (ECMO). PCR for SARS‐CoV‐2 and human metapneumovirus (hMPV) was positive in BALF. The patient developed severe intrapulmonary bleeding from the right main bronchus, which was stanched by cold lavages and instillation of tranexamic acid. BALF culture grew *Aspergillus fumigatu*s, was positive for galactomannan, and intravenous voriconazole treatment was commenced.

![Chest CT images of patients with COVID‐19 Associated Invasive Pulmonary Aspergillosis. A, Patient \#1: Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations. B, Patient \#2: Ground‐glass opacities with small nodular infiltrations of up to 1 cm. C, Patient \#3: Bilateral ground‐glass opacities diffuse nodular infiltrates and cystic cavities and partly air crescent sign. D, Patient \#4: Bullous emphysema and ground‐glass opacities, interstitial changes and consolidations with nodular infiltrates. E, Patient \#5: Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates](MYC-63-528-g001){#myc13096-fig-0001}

A 70‐year‐old man was admitted to the ICU because of ARDS with a Horowitz‐Index of 93 mm Hg. PCR on BALF was tested positive for hMPV, SARS‐CoV‐2 and *Aspergillus fumigatus*. Two days before, serum galactomannan had turned positive. BALF was tested positive for galactomannan. Chest CT showed ground‐glass opacities with some small nodular infiltrations of up to 1 cm (Video [S2](#myc13096-sup-0002){ref-type="supplementary-material"}, patient \#2 Figure [1B](#myc13096-fig-0001){ref-type="fig"}). Due to acute renal failure requiring slow low‐efficient daily dialysis (SLEDD) and elevated liver enzymes, intravenous isavuconazole treatment was started.

A 54‐year‐old man presented with ARDS with a Horowitz‐Index of 128 mm Hg. TA revealed SARS‐CoV‐2 PCR positive and *Aspergillus fumigatus* in culture. BALF was positive for galactomannan. Chest CT showed bilateral ground‐glass opacities, diffuse nodular infiltrates and cystic cavities and partly air crescent sign (Video [S3](#myc13096-sup-0003){ref-type="supplementary-material"}, patient \#3 Figure [1C](#myc13096-fig-0001){ref-type="fig"}). Intravenous voriconazole treatment was initiated.

A 73‐year‐old man was transferred to the ICU due to ARDS with PCR on TA tested positive for SARS‐CoV‐2, and *Aspergillus fumigatus* that also grew in culture. Chest CT showed known bullous emphysema with ground‐glass opacities and consolidations with nodular infiltrates (Video [S4](#myc13096-sup-0004){ref-type="supplementary-material"}, patient \#4, Figure [1D](#myc13096-fig-0001){ref-type="fig"}). Intravenous voriconazole was begun.

A 54‐year‐old woman was transferred to the ICU due to ARDS with PCR on TA tested positive for SARS‐CoV‐2. Serum galactomannan returned positive in two consecutive serum samples. Chest CT showed bilateral ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video [S5](#myc13096-sup-0005){ref-type="supplementary-material"}, patient \#5, Figure [1E](#myc13096-fig-0001){ref-type="fig"}). Intravenous caspofungin was started. No autopsies were performed. Detailed patient characteristics are given in Table [1](#myc13096-tbl-0001){ref-type="table"}.

4. DISCUSSION {#myc13096-sec-0008}
=============

Patients with ARDS triggered by viral infection, in particular influenza, are prone to invasive aspergillosis even in absence of prior immunodeficiency.[^2^](#myc13096-bib-0002){ref-type="ref"}, [^3^](#myc13096-bib-0003){ref-type="ref"} We report putative IPA in five of 19 COVID‐19 patients with moderate to severe ARDS without underlying immunocompromising disease on two separate ICUs.

Spontaneous intrapulmonary bleeding and haemoptysis are typical complications of IPA. Ground‐glass opacities characterise COVID‐19 as well as IPA, thus comprehensive microbiological evaluation can prevent missing IPA.

By applying strict interpretation of the host and risk factors for invasive aspergillosis according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group definitions the risk of missed diagnosis increases in the COVID‐19 population.[^8^](#myc13096-bib-0008){ref-type="ref"} However, a most complicated issue in ARDS patients is to differentiate *Aspergillus* colonisation from invasive disease---especially as radiological imaging is non‐specific. To address this issue, a consensus project will seek to provide standard definitions for invasive fungal disease in critically ill adult patients.[^10^](#myc13096-bib-0010){ref-type="ref"}

Our observations suggest increased risk for critically ill COVID‐19 patients to develop co‐infection with *Aspergillus*, which is likely to increase mortality rates further. Therefore, testing for the presence of *Aspergillus* in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered.[^11^](#myc13096-bib-0011){ref-type="ref"}

Our findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.
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